Humacyte, Inc. (HUMA)
(Real Time Quote from BATS)
$1.54 USD
-0.05 (-3.15%)
Updated Nov 4, 2025 10:22 AM ET
3-Hold of 5 3
NA Value NA Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HUMA 1.54 -0.05(-3.15%)
Will HUMA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.

        
Zacks News for HUMA
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Other News for HUMA
Is HUMA setting up for a drop? Fell Below 50 Day Moving Average shows up after slipping 4.79%
Is HUMA building bullish momentum? Crossed Above 50 Day Moving Average shows up after advancing 3.09%
HUMA Fell Below 50 Day Moving Average on October 30
Is HUMA primed for downward momentum? 20 Day Moving Average Resistance shows up after slipping 0.59%
Humacyte announces publication of new data on Symvess